For US payers, pegfilgrastim is a less-expensive choice than daily filgrastim for reducing the risk of febrile neutropenia in patients receiving myelosuppressive chemotherapy.
Michelle E. Skornicki, MPH
Advertisement
Articles by Michelle E. Skornicki, MPH
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
First-Ever Guideline on Cardio-Kidney-Metabolic Syndrome Calls for Earlier Screening, Coordinated Care
2
Anticoagulation in AFib: Risk Stratification, Therapy Selection, and Factor XI Inhibitors
3
GLP-1 Counseling Pearls: 7 Things Every Pharmacist Should Know
4
Vigilance in an Age of Misinformation: Rebuilding Trust Through Evidence and Connection
5